Company: Theratechnologies Inc.
Job title: SrVP & CMO
Moving From Bench to Bedside: Transitioning the Novel PDC TH1902 From the Preclinical to the Clinical Setting 2:30 pm
Sortilin is a novel receptor overexpressed in cancer, whose normal function as a scavenger receptor can be exploited to rapidly transport cytotoxic drugs into cancer cells Learn about the validation of the unique MoA and kinetics of internalization of TH1902 into the cancer cells Gain insight into the status of the Phase I Study (Part…Read more
day: Scientific Program Day One